US Patent Issued to PERSONGEN BIOTHERAPEUTICS (SUZHOU) on Nov. 3 for "Human CD276-targeting monoclonal antibody and application thereof" (Chinese Inventors)

ALEXANDRIA, Va., Nov. 3 -- United States Patent no. 12,779,024, issued on Nov. 3, was assigned to PERSONGEN BIOTHERAPEUTICS (SUZHOU) Co. LTD. (Jiangsu, China).

"Human CD276-targeting monoclonal antibody and application thereof" was invented by Lin Yang (Suzhou, China) and Fengtao You (Suzhou, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a human CD276-targeting monoclonal antibody and an application thereof. Specifically, provided are a CD276-targeting antibody, which has a high affinity and a high specificity for human CD276. Further provided are a pharmaceutical composition and a cell containing the antibody, as well as a preparation method for the antibody and an application."

The pat...